The novel class of integrin/MDM2 inhibitors is useful in the subpopulation of patients with glioblastoma expressing functional p53 concomitantly with a high level of α5β1 integrin (Merlino et al., 2018). This evidence concerns the gene TP53 and glioblastoma.